SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (date of earliest event
reported): November 13, 2012
TONIX PHARMACEUTICALS HOLDING CORP.
(Exact name of registrant as specified
in its charter)
(State or Other Jurisdiction
509 Madison Avenue, Suite 306, New York,
New York 10022
(Address of principal executive offices)
Registrant’s telephone number,
including area code: (212) 980-9155
Copy of correspondence to:
Marc J. Ross, Esq.
Harvey Kesner, Esq.
James M. Turner, Esq.
Sichenzia Ross Friedman Ference LLP
New York, New York 10006
Tel: (212) 930-9700 Fax: (212) 930-9725
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 8.01 Other Events.
On November 13, 2012, Tonix Pharmaceuticals
Holding Corp. (the “Company”) issued a press release announcing detailed results from its pre-clinical study of cyclobenzaprine,
the active ingredient of the Company’s lead candidate, TNX-102 sublingual tablet.
A copy of the press release that discusses
this matter is filed as Exhibit 99.01 to, and incorporated by reference in, this report. The information in this Current Report
is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934
or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference
into any registration statement or other document pursuant to the Securities Act of 1933, except as shall be expressly set forth
by specific reference in any such filing.
ITEM 9.01 Financial Statements and Exhibits.
|99.01||Press Release, dated November 13, 2012, issued by Tonix Pharmaceuticals Holding Corp.|
Pursuant to the requirement
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
||TONIX PHARMACEUTICALS HOLDING
|Date: November 13, 2012
||By: /s/ SETH LEDERMAN|
||President and Chief Executive Officer|